Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Stock Information for Oncternal Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oncternal Therapeutics Inc.

Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.